DUALITYBIO-B's New Drug Application for HER2-Positive Breast Cancer Accepted by NMPA

Stock News04-09 18:54

DUALITYBIO-B (09606) has announced that its Biologics License Application (BLA) for DB-1303/BNT323 has been accepted by the National Medical Products Administration (NMPA). This submission is based on positive outcomes from the pivotal Phase III clinical trial, designated DB-1303-O-3001, and feedback received during pre-submission communications with the Center for Drug Evaluation of the NMPA.

The DB-1303-O-3001 trial is a randomized, controlled, open-label, multicenter Phase III study designed to evaluate the efficacy and safety of DB-1303 compared to T-DM1 in adults with HER2-positive unresectable or metastatic breast cancer who have previously been treated with trastuzumab and a taxane.

Following an assessment by the Independent Data Monitoring Committee (IDMC), the Phase III trial has met its primary endpoint of progression-free survival (PFS). A prespecified interim analysis demonstrated that DB-1303 showed a statistically significant and clinically meaningful improvement in the primary endpoint compared to the control group, with a favorable safety and tolerability profile.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1150883471?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-09 18:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150883471","market":"sg","top_or_hot":-1,"title":"DUALITYBIO-B's New Drug Application for HER2-Positive Breast Cancer Accepted by NMPA","media":"Stock News","content":"<p>DUALITYBIO-B (09606) has announced that its Biologics License Application (BLA) for DB-1303/BNT323 has been accepted by the National Medical Products Administration (NMPA). This submission is based on positive outcomes from the pivotal Phase III clinical trial, designated DB-1303-O-3001, and feedback received during pre-submission communications with the Center for Drug Evaluation of the NMPA.</p>\n<p>The DB-1303-O-3001 trial is a randomized, controlled, open-label, multicenter Phase III study designed to evaluate the efficacy and safety of DB-1303 compared to T-DM1 in adults with HER2-positive unresectable or metastatic breast cancer who have previously been treated with trastuzumab and a taxane.</p>\n<p>Following an assessment by the Independent Data Monitoring Committee (IDMC), the Phase III trial has met its primary endpoint of progression-free survival (PFS). A prespecified interim analysis demonstrated that DB-1303 showed a statistically significant and clinically meaningful improvement in the primary endpoint compared to the control group, with a favorable safety and tolerability profile.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DUALITYBIO-B's New Drug Application for HER2-Positive Breast Cancer Accepted by NMPA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDUALITYBIO-B's New Drug Application for HER2-Positive Breast Cancer Accepted by NMPA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-09 18:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>DUALITYBIO-B (09606) has announced that its Biologics License Application (BLA) for DB-1303/BNT323 has been accepted by the National Medical Products Administration (NMPA). This submission is based on positive outcomes from the pivotal Phase III clinical trial, designated DB-1303-O-3001, and feedback received during pre-submission communications with the Center for Drug Evaluation of the NMPA.</p>\n<p>The DB-1303-O-3001 trial is a randomized, controlled, open-label, multicenter Phase III study designed to evaluate the efficacy and safety of DB-1303 compared to T-DM1 in adults with HER2-positive unresectable or metastatic breast cancer who have previously been treated with trastuzumab and a taxane.</p>\n<p>Following an assessment by the Independent Data Monitoring Committee (IDMC), the Phase III trial has met its primary endpoint of progression-free survival (PFS). A prespecified interim analysis demonstrated that DB-1303 showed a statistically significant and clinically meaningful improvement in the primary endpoint compared to the control group, with a favorable safety and tolerability profile.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1150883471","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150883471","pubTimestamp":1775732071,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"DUALITYBIO-B (09606) has announced that its Biologics License Application (BLA) for DB-1303/BNT323 has been accepted by the National Medical Products Administration (NMPA). This submission is based...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","IPOS":"Renaissance International IPO ETF","HK0000252160.HKD":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","DB":"德意志银行","BK4566":"资本集团","BK4552":"Archegos爆仓风波概念","BK4118":"综合性资本市场","HK0000500386.USD":"易方达 (香港) 中国股票股息基金A 类 (累积) 美元","09606":"映恩生物-B","HK0000252152.HKD":"易方达 (香港) 中国股票股息基金A 类 (累积) 港元","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"DualityBio-B HER2阳性乳腺癌新药申请获NMPA受理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DB":1,"IPOS":1,"09606":1},"content_text":"DUALITYBIO-B (09606) has announced that its Biologics License Application (BLA) for DB-1303/BNT323 has been accepted by the National Medical Products Administration (NMPA). This submission is based on positive outcomes from the pivotal Phase III clinical trial, designated DB-1303-O-3001, and feedback received during pre-submission communications with the Center for Drug Evaluation of the NMPA.\nThe DB-1303-O-3001 trial is a randomized, controlled, open-label, multicenter Phase III study designed to evaluate the efficacy and safety of DB-1303 compared to T-DM1 in adults with HER2-positive unresectable or metastatic breast cancer who have previously been treated with trastuzumab and a taxane.\nFollowing an assessment by the Independent Data Monitoring Committee (IDMC), the Phase III trial has met its primary endpoint of progression-free survival (PFS). A prespecified interim analysis demonstrated that DB-1303 showed a statistically significant and clinically meaningful improvement in the primary endpoint compared to the control group, with a favorable safety and tolerability profile.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1150883471","isCrawlerRequest":true}